In addition, to assess for the effect of hAMSC injection on the differentiation of GBM cells in vivo, we performed immunostaining for Nestin, GFAP/human nuclei, and Tuj1 on perfused brain sections 3 weeks after hAMSCs were administered to human GBM-bearing mice (Figure 4g). This evidence concerns the gene GFAP and glioblastoma.